For how we live.
An industry-standard indirect comparison of fezolinetant and elinzanetant found comparable reductions in vasomotor symptoms. Elinzanetant improved sleep disturbance more, without a difference in overall quality of life.
Lynkuet is the second neurokinin-targeted drug cleared in the US for vasomotor symptoms. The trials found no hepatotoxic effects; FDA still asked for three years of enhanced liver-injury reporting.
Seven of those nine were denosumab. The committee's September opinions also covered an RSV antibody for infants, a first EU treatment for IgG4-related disease, and four withdrawn applications.